New Trial From Medical Lead Management Software Provider Spectranetics

Officials with Spectranetics Corporation said that the Excite ISR clinical trial will enroll up to 353 patients at up to 30 sites in the U.S. The trial will study femoropopliteal in-stent restenosis (ISR), a condition caused by the development of neointimal hyperplasia within a previously implanted stent.
TMCNet